Compare
Liminatus Pharma, Inc. vs Adaptin Bio, Inc. vs Brainstorm Cell Therapeutics Inc. vs Abpro Holdings, Inc.
| Latest fiscal year | Liminatus Pharma, Inc. LIMN | Adaptin Bio, Inc. APTN | Brainstorm Cell Therapeutics Inc. BCLI | Abpro Holdings, Inc. ABPO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | n/a | n/a |
| Revenue growth (YoY) | n/a | n/a | n/a | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/a | n/a |
| Net margin | n/a | n/a | n/a | n/a |
| Net income | -$10.21M | -$5.17M | -$10.31M | -$2.89M |
| EPS (Diluted) | -$0.43 | -$0.66 | -$1.11 | -$1.30 |
| Operating cash flow | -$9.96M | -$4.78M | -$6.97M | -$6.01M |
| Free cash flow | -$9.98M | n/a | n/a | n/a |
| Cash & equivalents | n/a | $459.2K | $29.0K | n/a |
| Total assets | $512.8K | $619.2K | $1.02M | $1.06M |
| Total liabilities | $10.33M | $2.11M | $11.01M | n/a |
| Shareholders' equity | -$9.81M | -$1.49M | -$9.98M | -$8.83M |
| Return on year-end equity | n/a | n/a | n/a | n/a |
| Shares outstanding | 27.06M | 8.66M | 11.03M | 2.73M |
Revenue, most recent five fiscal years
| Fiscal year | Liminatus Pharma, Inc. | Adaptin Bio, Inc. | Brainstorm Cell Therapeutics Inc. | Abpro Holdings, Inc. |
|---|---|---|---|---|
| Latest | n/a | n/a | n/a | $183.0K Ended 2024-12-31 |
| 1 year earlier | n/a | n/a | n/a | $122.0K Ended 2023-12-31 |
| 2 years earlier | n/a | n/a | n/a | n/a |
| 3 years earlier | n/a | n/a | n/a | n/a |
| 4 years earlier | n/a | n/a | n/a | n/a |